Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training (HyperLa)

July 20, 2026 updated by: Prof. Dr. Henning Wackerhage, Technical University of Munich

HyperLa: Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training: A Multi-centre Study by the HyperLa Study Group

The HyperLa study investigates whether a person's "glycolyticness"-the efficiency with which their body uses glycolysis for energy-can predict how much their muscles will grow (hypertrophy) in response to resistance training. Participants will undergo a specialized "vLapeak" test, which measures the maximal rate of lactate accumulation during a 10-second all-out cycling sprint, to determine their individual glycolytic power. Following this initial assessment, participants will complete eight weeks of standardized, twice-weekly resistance training focused on the lower body. The study aims to determine if individuals with higher initial vLapeak values experience greater increases in muscle size compared to those with lower values. This research may help explain why people respond differently to exercise and support the development of personalized training programs.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This multicentre, prospective, single-arm interventional cohort study aims to link metabolic phenotypes with physical adaptations.

  • Primary Assessment: Glycolytic power is quantified via the vLapeak test, defined as the peak rate of blood lactate accumulation during a 10-second isokinetic or sprint-configured cycle ergometry test.
  • Intervention: The 8-week resistance training program consists of two supervised sessions per week. Exercises include the leg press (or Smith-machine squat) and leg extensions, performed for 4 sets of 8-12 repetitions. Intensity progresses from an RPE of 6 to voluntary muscular failure by the third week.
  • Measurements: Muscle hypertrophy is primarily assessed via ultrasound measurement of muscle thickness and cross-sectional area (CSA) of the thigh muscles before and after the intervention.
  • Secondary Objectives: The study also evaluates changes in the plasma metabolome via venous blood samples and, at select sites, analyzes muscle biopsies for glycolytic enzyme activity and fiber type composition to further validate the vLapeak results.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Finland
    • Central Finland
      • Jyväskylä, Central Finland, Finland, 40014
        • Recruiting
        • University of Jyväskylä, Faculty of Sport and Health Sciences
        • Contact:
  • Germany
    • Bavaria
      • München, Bavaria, Germany, 80809
        • Recruiting
        • Technical University of Munich, TUM School of Medicine and Health
        • Contact:
        • Contact:
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Germany, 51147
        • Recruiting
        • DLR Cologne, Department of Metabolism and Human Performance
        • Contact:
      • Düsseldorf, North Rhine-Westphalia, Germany, 40233
    • Saxony
      • Chemnitz, Saxony, Germany, 09126
        • Recruiting
        • TU Chemnitz, Sports Medicine and Exercise Therapy
        • Contact:
      • Leipzig, Saxony, Germany, 04109
        • Recruiting
        • Institute for Applied Training Science (IAT) Leipzig
        • Contact:
  • Ireland
    • Limerick
      • Limerick, Limerick, Ireland, V94 T9PX
        • Recruiting
        • University of Limerick, Department of Physical Education and Sport Sciences (PESS)
        • Contact:
  • Spain
    • Madrid
      • Madrid, Madrid, Spain, 28040
        • Recruiting
        • Universidad Politécnica de Madrid, Facultad de Ciencias de la Actividad Física y del Deporte (INEF)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Body Mass Index (BMI) between 20-29 kg/m2
  • No structured resistance training performed in the last twelve months.
  • Maximum of four sessions per week of recreational or low-to-moderate aerobic endurance activity.
  • No history of competitive strength or physique sports.

Exclusion Criteria:

  • Diagnosed cardiovascular, pulmonary, metabolic, neuromuscular, or orthopaedic disease that contraindicates exercise.
  • Positive response to any question on the PAR-Q 2025 questionnaire.
  • Current use of anabolic steroids, creatine, or other substances known to strongly influence muscle hypertrophy.
  • Regular engagement in shift work.
  • Women who are pregnant or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Resistance Training Group
Participants in this single-arm cohort will undergo an 8-week standardized, hypertrophy-focused lower-body resistance training program.
Behavioral: Hypertrophy-focused Resistance Training
Standardized training consisting of twice-weekly supervised sessions for 8 weeks. Each session includes 4 sets of 8-12 repetitions of leg press (or Smith-machine squat) and leg extensions. Training intensity progresses from an RPE of 6 to voluntary muscular failure starting from week three.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in mid-thigh Muscle Thickness
Time Frame: Baseline and Week 8 (completion of training intervention)
Change in mid-thigh muscle thickness (combination of rectus femoris and vastus intermedius) as measured by ultrasound.
Baseline and Week 8 (completion of training intervention)
Change in lateral-thigh Muscle Thickness
Time Frame: Baseline and Week 8 (completion of training intervention)
Change in lateral thigh muscle thickness (combination of vastus lateralis and vastus intermedius) as measured by ultrasound.
Baseline and Week 8 (completion of training intervention)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Peak Rate of Blood Lactate Accumulation (vLapeak)
Time Frame: Baseline and Week 8 (completion of training intervention)
Peak rate of blood lactate accumulation before and after a 10-second all-out seated cycle ergometry test. Blood lactate will be sampled every minute for 10 minutes post-test to capture the peak value.
Baseline and Week 8 (completion of training intervention)
Change in Vastus Lateralis Muscle Cross-Sectional Area (CSA)
Time Frame: Baseline and Week 8 (completion of training intervention)
Change in cross-sectional area of the vastus lateralis at 50% of muscle length measured via ultrasound.
Baseline and Week 8 (completion of training intervention)
Maximal Strength (3RM) for Leg Press
Time Frame: Baseline and Week 8 (completion of training intervention)
Change in 3-Repetition Maximum (3RM) for the leg press exercise to assess lower-body multi-joint maximal strength.
Baseline and Week 8 (completion of training intervention)
Maximal Strength (3RM) for Leg Exentsion
Time Frame: Baseline and Week 8 (completion of training intervention)
Change in 3-Repetition Maximum (3RM) for the leg extension exercise to assess single-joint quadriceps strength.
Baseline and Week 8 (completion of training intervention)
Change in Relative Abundance of Selected Plasma Metabolites
Time Frame: Baseline and Week 8 (completion of training intervention)
Change in the relative concentration of targeted plasma metabolites from baseline to Week 8, as analyzed via mass spectrometry.
Baseline and Week 8 (completion of training intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Technical University of Munich

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
DLR German Aerospace Center
University of Limerick
University of Jyvaskyla
Chemnitz University of Technology
IST University of Applied Sciences Düsseldorf
Institute for Applied Training Science (IAT/FES e.V.)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 4, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 23, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 23, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HyperLa

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

A formal plan for sharing individual participant data (IPD) with external researchers has not yet been finalized. The study involves a multicentric international consortium with strict data protection requirements under GDPR. Data is currently managed centrally via REDCap at the Technical University of Munich. Requests for data sharing will be considered on a case-by-case basis by the HyperLa Study Group after the primary publication of results, and would require a formal proposal and a signed Data Access or Material Transfer Agreement (MTA)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings